Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,359 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma(PRISM) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | withdrawn | Phase 1 / Phase 2 | 0 | Lisata Therapeutics, Inc.INDUSTRY | 0 | Jun 6, 2025 | clinicaltrials |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of RochesterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | withdrawn | Phase 2 | 0 | HonorHealth Research InstituteOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Mar 23, 2023 | clinicaltrials |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol(LIDA-ADJ) | withdrawn | Phase 2 | 0 | University Hospital, MontpellierOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Walid Shaib, MDOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma(TheraBionics) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | withdrawn | Phase 2 | 0 | A2 Healthcare Taiwan CorporationINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2026source: clinicaltrials